ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Transcatheter

August 29, 2019
Using an approach that minimizes valve depth relative to the membranous septum, the authors reduced the need for permanent pacemaker placement to a reliable and predictable 3% compared to the accepted standard of 10%.
August 25, 2019
In an era of increased use of MitraClip, surgical mitral valve repair still offers a durable solution.  Tirone David and colleages report 1,234 consecutive patients who had mitral valve repair with 20 year follow-up.  
August 16, 2019
The FDA-approved use of TAVR has now expanded to low-risk patients with severe aortic stenosis.  This includes both Edwards Lifesciences' Sapien 3 and Sapien 3 Ultra as well as Medtronic's  Evolut R and Evolut PRO.   
August 14, 2019
Filmed at the Heart Valve Society Annual Meeting 2019 in Sitges, Spain, Sir Magdi Yacoub and Patrick Serruys discuss the future of tissue engineered valves.
July 24, 2019
The authors report a case of early migration of a self-expanding transcatheter aortic valve prosthesis causing coronary obstruction and myocardial infarction.
July 20, 2019
This retrospective study by Sedeek et al aimed to compare the outcomes of patients undergoing transcatheter aortic valve replacement (TAVR) valve-in-valve (n=90) versus surgical replacement (SAVR) (n=260) of failing stented aortic biological valves in a cohort of 350 patients .
July 16, 2019
Abbott announced that its fourth-generation MitraClip device, MitraClip G4, was approved by the US Food and Drug Administration on July 15, 2019, to treat mitral regurgitation (MR) in a wider population of patients.  The MitraClip G4 include new clip sizes and an enhanced leaflet grasping feature
July 9, 2019
Transcatheter aortic valve replacement (TAVR) is expanding to younger patients, but the feasibility of TAVR in failing transcatheter aortic valves (TAV) remains unknown.

Pages